Clinical Studies
Breast Care
Cardiology
Colon Cancer
Dermatology
Diabetes
Gastrointestinal
HIV/AIDS
Mental Health
Neurology
NeuroOphthalmology
Obesity/Weight Management
Women's Health
Other
Special Features
Advances/Research
| Principal Investigator: | Mala Varma, MD | |
| Co-investigators: | Michael Grossbard MD, Ibrahim Nakhoul MD, Peter Kozuch MD, IIan Shapira MD, Bruce Culliney MD, Ralph Zalusky MD | |
| Time frame of study: | Ongoing | |
| Time frame of participation: | 2 years | |
| Number of participants needed: | 26 | |
| Location of Study: | St.
Luke's-Roosevelt Hospital Center |
|
| Contact Name, Number & Email: | Mala
Varma MD, 212-844-6286 mvarma@chpnet.org |
Summary:
St Luke’s-Roosevelt Hospital Center and Beth Israel Medical Center's Clinical Research Office is conducting a research study for the combination of anti-Rh(D) and danazol in patient with Immune Thrombocytopenic Purpura (ITP). This study will determine if danazol is an anti-Rh(D)-sparing agent and that the addition of danazol to anti-Rh(D) may decrease the requirement for anti-Rh (D) and even conclude the need for continued anti-Rh(D) after one year.
Criteria for Participation:
Patients diagnosed with Immune thrombocytopenic purpura at least 18 years of age who have platelets less than 30,000/µl.
Benefit of Participation:
There may or may not be direct medical benefit to you. We hope the information learned from this study will benefit other subjects with ITP in the future.